Eko Low Ejection Fraction Tool (ELEFT) vs Us2.ai
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A is designed for early screening of low ejection fraction during routine physical exams using digital stethoscopes, aiming for proactive identification of heart failure risk. Tool B, on the other hand, automates the comprehensive analysis of echocardiograms to generate detailed reports and detect various cardiac conditions, streamlining the diagnostic process after an echo has been performed. Therefore, Tool A is suited for initial risk assessment in primary care, while Tool B is for efficient, in-depth diagnostic analysis in specialized cardiology settings.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Eko's ELEFT integrates with routine physical exams using an Eko digital stethoscope, providing low ejection fraction detection results in approximately 15 seconds. Us2.ai automates the analysis of existing echocardiogram images, generating structured reports with zero manual clicks, fitting into the workflow of an echo lab.
Us2.ai offers robust integration with PACS, CVIS, EMR, and ultrasound devices via DICOM and HL7, allowing structured reports to be delivered directly into existing systems. ELEFT integrates with Eko digital stethoscopes and utilizes cloud-based data processing, but specific EHR integration depth beyond this is not explicitly detailed.
ELEFT's primary function is to aid in the early detection of low ejection fraction (LVEF u2264 40%), a key indicator of heart failure. Us2.ai provides comprehensive automated echocardiography analysis, including detection of cardiac amyloidosis, heart failure (HFrEF and HFpEF), aortic stenosis, and pulmonary hypertension, along with detailed measurements across all heart chambers.
ELEFT is designed to integrate into a familiar stethoscope-based physical exam, suggesting a low learning curve for quick screening. Us2.ai aims for a 'zero-click' automated analysis, which, once integrated into existing systems, minimizes manual intervention, though initial setup and understanding of its comprehensive reports may require some training.
Us2.ai explicitly allows for editable AI outputs and annotations, giving clinicians the ability to review and adjust measurements, and it includes features for audit logging, particularly for core lab solutions. ELEFT's description does not specifically mention audit trail or editability features for its low EF detection results.
ELEFT's integration with Eko stethoscopes and a cloud platform suggests a potentially streamlined rollout across multiple sites where Eko stethoscopes are used. Us2.ai's deep integration capabilities with PACS, CVIS, and EMR systems via DICOM and HL7 would require careful planning to align with each site's specific IT infrastructure and existing workflows.
ELEFT has demonstrated a sensitivity of 74.7% and a specificity of 77.5% for detecting LVEF u2264 40% in a clinical study, with an independent validation showing 84.8% sensitivity and 69.5% specificity. Us2.ai's automated measurements have shown good to excellent agreement with expert clinicians across various echocardiographic parameters, with specific studies reporting 82.8% sensitivity and 95.2% specificity for cardiac amyloidosis detection, and 100% sensitivity for pulmonary hypertension and severe aortic stenosis.
More Comparisons
Backers
Who funded each tool's parent company.